Adalimumab biosimilar (Reliance Life Sciences)

阿达木单抗生物类似药（Reliance Life Sciences）

Report date: 2022/01/14 13:23:58

Base Information

Drug NameAdalimumab biosimilar (Reliance Life Sciences)
Drug Alias Name阿达木单抗生物仿制药（Reliance Life Sciences）Adfrar IBR-TPR-021
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionTumor necrosis factor α inhibitors
TargetsTumor necrosis factor α
Therapy Area/IndicationsPsoriasisColitis, UlcerativeArthritis, Rheumatoid +[5] 
Global Approved IndicationsPsoriasisColitis, UlcerativeArthritis, Rheumatoid +[5] 
Approved Indications in ChinaN/A
Original Approved Country/TerritoryIndia
Original Approved Date2016/01/12
Country/TerritoryIndia
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesReliance Life Sciences
China Registration ClassN/A

Develop Information

Active CompaniesTorrent PharmaReliance Life Sciences
Inactive CompaniesN/A
Active IndicationsPsoriasisColitis, UlcerativeArthritis, Rheumatoid +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeL04AB04
Related LinksN/A